In vivo screening of multiple bacterial strains identifies Lactobacillus rhamnosus Lb102 and Bifidobacterium animalis ssp. lactis Bf141 as probiotics that improve metabolic disorders in a mouse model of obesity

Abstract

Given the growing evidence that gut dysfunction, including changes in gut microbiota composition, plays a critical role in the development of inflammation and metabolic diseases, the identification of novel probiotic bacteria with immunometabolic properties has recently attracted more attention. Herein, bacterial strains were first isolated from dairy products and human feces and then screened in vitro for their immunomodulatory activity. Five selected strains were further analyzed in vivo, using a mouse model of diet‐induced obesity. C57BL/6 mice were fed a high‐fat high‐sucrose diet, in combination with 1 of 3 Lactobacillus strains (Lb38, L. plantarum; L79, L. paracaseil casei; Lbl02, L. rhamnosus) or Bifidobacterium strains (Bf26, Bfl41, 2 different strains of B. animalis ssp. lactis species) administered for 8 wk at 109 colony‐forming units/d. Whereas 3 strains showed only modest (Lb38, Bf26) or no (L79) effects, Lbl02 and Bfl41 reduced diet‐induced obesity, visceral fat accretion, and inflammation, concomitant with improvement of glucose tolerance and insulin sensitivity. Further analysis revealed that Lbl02 and Bf141 enhanced intestinal integrity markers in association with selective changes in gut microbiota composition. We have thus identified 2 new potential probiotic bacterial strains with immunometabolic properties to alleviate obesity development and associated metabolic disturbances.—Le Barz, M., Daniel, N., Varin, T. V., Naimi, S., Demers‐Mathieu, V., Pilon, G., Audy, J., Laurin, E., Roy, D., Urdaci, M. C., St‐Gelais, D., Fliss, I, Marette, A. In vivo screening of multiple bacterial strains identifies Lactobacillus rhamnosus Lbl02 and Bifidobacterium animalis ssp. lactis Bf 141 as probiotics that improve metabolic disorders in a mouse model of obesity. FASEB J. 33, 4921—4935 (2019). http://www.fasebj.org

Probiotic Mixture of Lactobacillus plantarum Strains Improves Lipid Metabolism and Gut Microbiota Structure in High Fat Diet-Fed Mice

“…Lactobacillus rhamnosus Lb102 and Bifidobacterium animalis ssp. lactis Bf141 isolated by Le Barz et al from fermented milk products and human feces, respectively, were used to interfere with mice fed with high-fat diet and it was found that they could effectively alleviate the onset of obesity and reduce the content of liver fat in mice (Le Barz et al, 2019).…”

Effect of Synbiotic Supplementation in a Very‐Low‐Calorie Ketogenic Diet on Weight Loss Achievement and Gut Microbiota: A Randomized Controlled Pilot Study

“…In particular, Lactobacillus rhamnosus and B. animalis spp. lactis , have been shown to reduce diet‐induced weight gain and also improve insulin sensitivity and glucose tolerance in animal models . The present study aims to investigate the changes produced in gut microbiota by a weight‐loss program based on a VLCKD followed by a low‐calorie diet (LCD), as well as whether the use of synbiotics is able to modulate gut microbiota diversity and composition and its association with gut permeability and inflammation.…”

Lactobacillus murinus Improved the Bioavailability of Orally Administered Glycyrrhizic Acid in Rats

“…Lactobacillus is one of the genera that are most commonly used as probiotics, which has exerted various beneficial functions on the host (Druart et al, 2014). L. rhamnosus GG was observed to ameliorate dextran sulfate sodium (DSS)-and oxazoloneinduced colitis through the activation of the epidermal growth factor receptor (EGFR) (Yan et al, 2011); the administration of L. rhamnosus LB102 reduced diet-induced obesity and inflammation, concomitant with the improvement of glucose tolerance and insulin sensitivity (Le Barz et al, 2019). L. murinus has also been reported to successfully colonize in rodent intestines and to possess protective properties for necrotizing enterocolitis (Isani et al, 2018).…”